Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 144-150

  Tsubota, Akihito ^a,b   Shimada, Noritomo ^c   Atsukawa, Masanori ^d   Abe, Hiroshi ^a   Kato, Keizo ^c   Ika, Makiko ^c   Matsudaira, Hiroshi ^b   Nagatsuma, Keisuke ^a,b   Matsuura, Tomokazu ^a   Aizawa, Yoshio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Shinmatsudo Central General Hospital   (Japan)

^d NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C virus infection; IL28B single nucleotide polymorphism; Pegylated interferon; Ribavirin; Sustained virological response; Telaprevir

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; INTERLEUKIN 28B GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

CHRONIC HEPATITIS C VIRUS INFECTION; IL28B SINGLE NUCLEOTIDE POLYMORPHISM; PEGYLATED INTERFERON; RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; TELAPREVIR;

ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897614360     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12402     Document Type: Article

References (30)

1. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 2006; 6: 3-16.
2. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009; 360: 1827-1838.
3. Hézode C, Forestier N, Dusheiko G etal. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009; 360: 1839-1850.
4. McHutchison JG, Manns MP, Muir AJ etal. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303.
5. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
6. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
7. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
8. Chayama K, Hayes CN, Abe H etal. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 2011; 204: 84-93.
9. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol. 2012; 56: 78-84.
10. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J. Viral Hepat. 2012; 19: e134-142.
11. INCIVEK. FDA Prescribing Information. Vertex Pharmaceuticals Incorporated, Cambridge, MA. May 2011. Cited 17 May 2013. Available from URL: http://pi.vrtx.com/files/uspi_telaprevir.pdf
12. INCIVOVR. European Medicines Agency. Summary of Product Characteristics. Janssen Cilag International NV, Beerse, Belgium. October 2011. Cited 17 May 2013. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf
13. TELAVIC. Health, Labour and Welfare Ministry. The Proper Usage Guideline for Telaprevir and Product Information. Mitsubishi Tanabe Pharma, Osaka, Japan. September 2011. Cited 17 May 2013. Available from URL: http://medical.mt-pharma.co.jp/intro/tlv/use/use00.shtml
14. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
15. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
16. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
17. Ge D, Fellay J, Thompson A etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
18. Okanoue T, Itoh Y, Hashimoto H etal. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J. Gastroenterol. 2009; 44: 952-963.
19. Tsubota A, Shimada N, Yoshizawa K etal. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. 2012; 32: 826-836.
20. Pol S, Aerssens J, Zeuzem S etal. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J. Hepatol. 2013; 58: 883-889.
21. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
22. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
23. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380.
24. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
25. Fellay J, Thompson AJ, Ge D etal. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
26. Thompson AJ, Fellay J, Patel K etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
27. Furusyo N, Ogawa E, Nakamuta M etal. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J. Hepatol. 2013; 59: 205-212.
28. De Meyer S, Dierynck I, Ghys A etal. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 2012; 56: 2106-2115.
29. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin. Infect. Dis. 2008; 46: 78-84.
30. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J. Hepatol. 2011; 55: 69-75.